Gonadotropin Releasing Hormone Agonist (GnRHa) Versus Estrogen and Progesterone for Luteal Support in High Responders
Status:
Recruiting
Trial end date:
2021-09-30
Target enrollment:
Participant gender:
Summary
Gonadotropin Releasing Hormone agonist (GnRHa) triggering is used as an alternative to human
chorionic gonadotropin (hCG) in GnRH antagonist protocol to eliminate the risk of ovarian
hyperstimulation syndrome (OHSS). However, its main disadvantage is a significantly lower
pregnancy rate, hypothesized to result from a process called "luteolysis" (demise of the
corpora lutea). In order to preserve a high pregnancy rates, several luteal support regimens
were investigated, including an intensive estrogen and progesterone supplementation and a
daily GnRHa treatment. However, no study, so far, compared the efficacy of these two
regimens. Our aim is to compare the efficacy of GnRHa versus estrogen and progesterone
supplementation for luteal phase support in high responders following GnRHa triggering.